These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32974950)

  • 1. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
    Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
    J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.
    Minami Y; Minami H; Miyamoto T; Yoshimoto G; Kobayashi Y; Munakata W; Onishi Y; Kobayashi M; Ikuta M; Chan G; Woolfson A; Ono C; Shaik MN; Fujii Y; Zheng X; Naoe T
    Cancer Sci; 2017 Aug; 108(8):1628-1633. PubMed ID: 28556364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
    Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
    Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
    J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
    Savona MR; Pollyea DA; Stock W; Oehler VG; Schroeder MA; Lancet J; McCloskey J; Kantarjian HM; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Cortes JE
    Clin Cancer Res; 2018 May; 24(10):2294-2303. PubMed ID: 29463550
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
    Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
    Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
    Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
    Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
    Shaik MN; Hee B; Wei H; LaBadie RR
    Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
    Shaik N; LaBadie RR; Hee B; Chan G
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
    Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
    Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer.
    Fostvedt LK; Shaik N; Martinelli G; Wagner AJ; Ruiz-Garcia A
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):927-935. PubMed ID: 33993815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
    Cortes JE; Dombret H; Merchant A; Tauchi T; DiRienzo CG; Sleight B; Zhang X; Leip EP; Shaik N; Bell T; Chan G; Sekeres MA
    Future Oncol; 2019 Nov; 15(31):3531-3545. PubMed ID: 31516032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
    Gerds AT; Tauchi T; Ritchie E; Deininger M; Jamieson C; Mesa R; Heaney M; Komatsu N; Minami H; Su Y; Shaik N; Zhang X; DiRienzo C; Zeremski M; Chan G; Talpaz M
    Leuk Res; 2019 Apr; 79():38-44. PubMed ID: 30849661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
    Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
    J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
    Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
    Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
    Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
    Shaik N; Hee B; Liang Y; LaBadie RR
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
    Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glasdegib: First Global Approval.
    Hoy SM
    Drugs; 2019 Feb; 79(2):207-213. PubMed ID: 30666593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.